Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1
…, T Higuchi, K Ikemoto, SI Niwa, T Ebihara… - Pharmaceutical …, 2006 - Springer
Purpose Stable transformants expressing human multidrug resistance 1 (MDR1), monkey
MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b in LLC-PK 1 …
MDR1, canine MDR1, rat MDR1a, rat MDR1b, mouse mdr1a, and mouse mdr1b in LLC-PK 1 …
Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome
K Hashimoto, T Uchiumi, T Konno, T Ebihara… - Hepatology, 2002 - journals.lww.com
Dubin-Johnson syndrome (DJS) is a hereditary disease characterized by hyperbilirubinemia.
We investigated the consequences of 2 missense mutations, R768W and Q1382R, of …
We investigated the consequences of 2 missense mutations, R768W and Q1382R, of …
Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury
…, M Johnson, S Yu, Y Moriya, T Ebihara… - Toxicological …, 2017 - academic.oup.com
Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the
treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects…
treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects…
[HTML][HTML] Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2
T Konno, T Ebihara, K Hisaeda, T Uchiumi… - Journal of Biological …, 2003 - ASBMB
The human multidrug resistance protein MRP1 and its homolog, MRP2, are both thought to
be involved in cancer drug resistance and the transport of a wide variety of organic anions, …
be involved in cancer drug resistance and the transport of a wide variety of organic anions, …
Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals
N Kawaguchi, T Ebihara, T Takeuchi, A Morohashi… - Xenobiotica, 2013 - Taylor & Francis
… Takuya EbiharaDrug Metabolism and Pharmacokinetics Research Laboratories,
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan …
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan …
Characterization of fasiglifam-related liver toxicity in dogs
…, Y Moriya, I Mori, L Pan, A Morohashi, T Ebihara… - Drug Metabolism and …, 2019 - ASPET
Fasiglifam, a potent and highly selective agonist of G protein-coupled receptor 40, was
developed for the treatment of type 2 diabetes mellitus. However, phase III clinical programs were …
developed for the treatment of type 2 diabetes mellitus. However, phase III clinical programs were …
Alternating terpolymerization of carbon dioxide, propylene oxide, and various epoxides with bulky side groups for the tuning of thermal properties
M Honda, T Ebihara, T Ohkawa, H Sugimoto - Polymer Journal, 2021 - nature.com
Terpolymerization of carbon dioxide (CO 2 ), propylene oxide (PO), and epoxide with bulky
side groups (styrene oxide (SO), cyclohexylethylene oxide (CyEO), tert-butylethylene oxide ( t …
side groups (styrene oxide (SO), cyclohexylethylene oxide (CyEO), tert-butylethylene oxide ( t …
Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK‐272 (SCO‐272), a novel orally active renin inhibitor
T Ebihara, M Nishihara, J Takahashi… - … & Drug Disposition, 2018 - Wiley Online Library
In the search for orally available drugs, the prediction of human pharmacokinetics (PK) is
essential for successfully selecting compounds that will be clinically useful. This report …
essential for successfully selecting compounds that will be clinically useful. This report …
Marked impact of P‐glycoprotein on the absorption of TAK‐427 in rats
…, S Yoshitomi, T Higuchi, T Ebihara… - … & drug disposition, 2008 - Wiley Online Library
The role of P‐glycoprotein (P‐gp, ABCB1) on the absorption process was investigated by
drug–drug interaction studies of TAK‐427 with P‐gp inhibitors (erythromycin, ketoconazole or …
drug–drug interaction studies of TAK‐427 with P‐gp inhibitors (erythromycin, ketoconazole or …
The effect of elevated α1-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats
T Ebihara, H Shimizu, M Yamamoto, T Higuchi… - Xenobiotica, 2019 - Taylor & Francis
The pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, was investigated
in rats with subcutaneously injected turpentine oil, which was an inflammation animal …
in rats with subcutaneously injected turpentine oil, which was an inflammation animal …